NEW YORK and BERLIN - atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company, announced the appointment of Anne Johnson as Chief Financial Officer (CFO). Johnson, who has served as the company's interim CFO since October 2023 and Chief Accounting Officer since August 2022, will succeed Stephen Bardin. Bardin will remain in an advisory capacity through March 31, 2024, to facilitate a smooth transition.
atai Life Sciences is focused on developing treatments for depression, anxiety, addiction, and other mental health disorders, aiming to address the substantial unmet need in the mental health treatment landscape. The company's approach includes pooling resources and best practices to expedite the development of new medicines that can lead to clinically meaningful and sustained behavioral change in mental health patients.
Johnson brings nearly two decades of experience in the biotechnology and pharmaceutical sectors to her new role. Her career includes senior leadership positions at Aruvant Sciences, Inc., Chimerix (NASDAQ:CMRX), Inc., PPD (NASDAQ:PPD), and Xanodyne Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.